Effect of Non-Surgical Periodontal Therapy on Serum Asprosin in Patients With Stable Angina
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 60
- Locations
- 1
Study Overview
Brief Summary
This study aims to evaluate the effect of non-surgical periodontal therapy on serum asprosin levels in patients with stable angina and periodontitis. Asprosin is a novel metabolic biomarker reported to have potential protective roles in cardiovascular diseases and inflammatory processes. The study also investigates the relationship between periodontal parameters and serum asprosin levels before and after periodontal therapy.
Detailed Description
Periodontitis is a chronic inflammatory disease characterized by the destruction of the tooth-supporting tissues and has been associated with increased systemic inflammation and cardiovascular diseases. Stable angina, a clinical manifestation of coronary artery disease, is closely linked to inflammatory and metabolic pathways. Increasing evidence suggests that periodontal inflammation may contribute to cardiovascular pathology through systemic dissemination of inflammatory mediators and oxidative stress mechanisms.
Asprosin is a recently identified adipokine secreted mainly from white adipose tissue and is involved in glucose metabolism, inflammatory regulation, and cardiovascular homeostasis. Previous studies have reported altered serum asprosin levels in patients with atherosclerosis, myocardial infarction, and periodontitis. However, the effect of periodontal therapy on serum asprosin levels in patients with stable angina has not yet been clinically investigated.
In this clinical study, 60 individuals will be allocated into three groups: healthy controls, periodontitis patients, and patients with stable angina and periodontitis. Non-surgical periodontal therapy will be performed in periodontitis groups, while supragingival scaling and oral hygiene instructions will be provided for controls. Clinical periodontal parameters and serum asprosin levels will be evaluated at baseline and at 3-month follow-up using ELISA analysis.
The study aims to determine whether periodontal therapy may influence serum asprosin levels and to evaluate the possible relationship between periodontal inflammation and metabolic-inflammatory pathways in cardiovascular disease. To the best of our knowledge, this is the first clinical study evaluating the effect of periodontal therapy on serum asprosin levels in patients with stable angina.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Willingness to participate in the study and provide written informed consent
- •Age 18 years or older
- •No periodontal treatment within the past 6 months
- •No use of local or systemic antibiotics within the past 3 months
Exclusion Criteria
- •Unwillingness to participate in the study or to provide informed consent
- •Age under 18 years
- •Use of local or systemic antibiotics for the treatment of widespread infection within the past 3 months
- •Receipt of periodontal treatment within the past 6 months
- •Pregnancy or lactation (for female participants)
- •History of acute myocardial infarction within the past 6 months
Investigators
Sena Altintas
Research assistant
Ondokuz Mayıs University